Modulatory effects mediated by metabotropic glutamate receptor 5 on lateral geniculate nucleus relay cells.
Glutamate is thought to be the excitatory neurotransmitter in the lateral geniculate nucleus (LGN) of the cat, mediating visual transmission from the retina via ionotropic receptors of both D,L-alpha-amino-3-hydroxy-5-alpha-methyl-4-isoxazolepropionate and N-methyl-D-aspartate subtypes. Moreover, glutamate also exerts an important modulatory influence on LGN cells, where metabotropic glutamate receptors (mGluRs) seem to play a crucial role. Here we show in anesthetized adult cats that iontophoretic application of the specific mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) produced two, distinctly different, effects on LGN neurons. Visual responses to flashing spots and drifting gratings were attenuated (decreased by an average of 59%) in 13 of 23 of the cells but augmented (increased by an average of 60%) in 10 of 23 of the cells. Further, in each case when the specific mGluR5 agonist (R,S)-2-chloro-5-hydroxyphenylglycine was applied, the effects obtained were the opposite to those of MPEP. Data obtained in a second group of experiments to determine a possible interaction between mGluR5 blockade by MPEP and glutamate ionotropic receptors show that, in the majority of neurons (11 of 15, 73%), the MPEP-mediated effects seem to be independent of N-methyl-D-aspartate and D,L-alpha-amino-3-hydroxy-5-alpha-methyl-4-isoxazolepropionate receptor activity. Our results demonstrate a physiological role for mGluR5 in controlling retinal input and show, in vivo, a more intricate scenario than previously suggested, highlighting the complexity of metabotropic receptor interactions with excitatory and inhibitory elements in the thalamus.
de Labra
Carmen
C
NEUROcom (Neuroscience and Motor Control Group), Department of Medicine and INEF-Galicia, Campus de Oza, University of A Coruña, 15006, A Coruña, Spain.
Rivadulla
Casto
C
Cudeiro
Javier
J
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D002415:Cats; D004347:Drug Interactions; D005260:Female; D005829:Geniculate Bodies / Q000166:cytology*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D007478:Iontophoresis / Q000379:methods; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010648:Phenylacetates / Q000494:pharmacology; D010775:Photic Stimulation / Q000379:methods; D011725:Pyridines / Q000494:pharmacology; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
C107349:2-chloro-5-hydroxyphenylglycine; D010648:Phenylacetates; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D016202:N-Methylaspartate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; C121465:6-methyl-2-(phenylethynyl)pyridine; D005998:Glycine